You searched for Cybin - Page 38 of 61

QualityStocksNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Ketamine Clinics Improving Accessibility and Reach, Helping Greatest Number of Patients

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is working to make psychedelic-based treatments more accessible and affordable by leveraging its growing chain of clinics in the United States. In 2021, Delic completed the acquisitions of Ketamine Infusion Centers (“KIC”) and Ketamine Wellness Centers (“KWC”). These acquisitions brought the number of operational … Continue reading “QualityStocksNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Ketamine Clinics Improving Accessibility and Reach, Helping Greatest Number of Patients”

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon Mydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds … Continue reading “Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics”

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeks to Capitalize on the Growing Market for Psychedelics in Healthcare

The global psychedelics market is estimated to hit $10.75 billion in 2027, with the alternative antidepressant drug market being valued at $15.98 billion in 2023 Already, 65% of individuals dealing with PTSD, depression, and anxiety in the United States believe that psychedelic medicine should be made available 83% of Americans living with these conditions are … Continue reading “Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeks to Capitalize on the Growing Market for Psychedelics in Healthcare”

QualityStocksNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Hails Potential of Promising Psychedelic Medicines

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform and a company making a mark in the psychedelic wellness scene, recently released results from a survey conducted on its behalf by The Harris Poll. According to a recent article, the survey showed that 65% of Americans who suffer from various conditions “believe that … Continue reading “QualityStocksNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Hails Potential of Promising Psychedelic Medicines”

QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, … Continue reading “QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs”

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available Studies such as these are helping … Continue reading “Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions”

Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Delic Labs to Present Latest Results and Insights from Its Extensive Experimental Studies on Cannabis Extraction at the Emerald Conference on February 28

Delic Lab’s President and Chief Science Officer, Dr. Markus Roggen, will present at the upcoming Emerald Conference on February 28 Delic Labs is a federally licensed research laboratory operating as part of the Delic Holdings ecosystem The laboratory focuses on extraction optimization, analytical testing, and chemical product and process development and is likely to continue … Continue reading “Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Delic Labs to Present Latest Results and Insights from Its Extensive Experimental Studies on Cannabis Extraction at the Emerald Conference on February 28”

QualityStocksNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Committed to Bringing Science-Backed Health Benefits to All, Reframing Psychedelic Conversation

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has sought to capitalize on the ongoing transformation within the mental health sector. The company is positioning itself as the United States’ leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation. This comes as Representative Earl Blumenauer … Continue reading “QualityStocksNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Committed to Bringing Science-Backed Health Benefits to All, Reframing Psychedelic Conversation”

QualityStocksNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company aiming to transform the treatment of mental health and addiction disorders. The company today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program (“SAP”), which allows health care providers to request specific drugs … Continue reading “QualityStocksNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program”

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans

Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022 The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University Mydecine also announced its partnership with Combat Stress to use psilocybin in a … Continue reading “Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans”

Site Search

Company Search

Search Results for: Cybin